Literature DB >> 17010933

Expression profiling characterization of laminin alpha-2 positive MDC.

Caterina Millino1, Milena Bellin, Marina Fanin, Chiara Romualdi, Elena Pegoraro, Corrado Angelini, Gerolamo Lanfranchi.   

Abstract

In the Caucasian population, patients affected by the most frequent forms of congenital muscular dystrophies (MDC) are commonly divided into two groups. The first is characterized by mutations of the gene for the laminin alpha-2 (LAMA2). The second is positive for this protein, highly heterogeneous, and has no specific genetic defect associated yet. We studied the skeletal muscle transcriptome of four LAMA2 deficient and six LAMA2 positive MDC patients by cDNA microarrays. The expression profiling defined two patients groups: one mild and one severe phenotype. This result was in agreement with histopathological features but only partially with the clinical classification. The mild phenotype is characterized by a delayed maturation from slow to fast muscle fibers. Other muscle transcripts, such as telethonin, myosin light-chains 3 and 1V, are underexpressed in this group. We suggest that expression profiling will provide important information to improve our understanding of the molecular basis of laminin alpha-2 positive MDC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17010933     DOI: 10.1016/j.bbrc.2006.09.063

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Overview of electrochemical DNA biosensors: new approaches to detect the expression of life.

Authors:  Stefano Cagnin; Marcelo Caraballo; Carlotta Guiducci; Paolo Martini; Marty Ross; Mark Santaana; David Danley; Todd West; Gerolamo Lanfranchi
Journal:  Sensors (Basel)       Date:  2009-04-24       Impact factor: 3.576

2.  Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy.

Authors:  Caterina Millino; Marina Fanin; Andrea Vettori; Paolo Laveder; Maria Luisa Mostacciuolo; Corrado Angelini; Gerolamo Lanfranchi
Journal:  BMC Med       Date:  2009-04-07       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.